Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.

作者
Binghe Xu,Qingyuan Zhang,Pin Zhang,Xichun Hu,Wěi Li,Zhongsheng Tong,Tao Sun,Yuee Teng,Xinhong Wu,Quchang Ouyang,Xi Yan,Jing Cheng,Qiang Liu,Jifeng Feng,Xiaojia Wang,Xiaoyu Zhu,Fei Wu,Xiao Zhang,Jianjun Zou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 1002-1002 被引量:9
标识
DOI:10.1200/jco.2021.39.15_suppl.1002
摘要

1002 Background: Dalpiciclib (SHR6390), a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer (ABC). Here we evaluated dalpiciclib with fulvestrant in ABC. Methods: In this randomized, double-blind, phase 3 trial, patients (pts) with HR+/HER2− locally advanced or metastatic breast cancer who had relapsed or progressed on previous endocrine therapy were enrolled. Eligible pts were randomized 2:1 to receive dalpiciclib (dalp; 150 mg po qd, d1-21, q4w) or placebo (PBO) with fulvestrant (fulv; 500 mg im, cycle 1 d1, d15, then d1 q4w). The primary endpoint was investigator (INV)-assessed PFS. As of Nov. 15, 2020, 162 (71.4% of total projected) events of disease progression or death had occurred and a preplanned interim analysis was done. The corresponding superiority boundary was 1-sided P = 0.0080 (Lan-DeMets [O’Brien-Fleming] boundary). Results: Overall, 361 pts were randomized to receive dalp-fulv (n = 241) or PBO-fulv (n = 120). With a median follow-up of 10.5 mo, dalp-fulv significantly improved INV-assessed PFS versus PBO-fulv (median, 15.7 [95% CI 11.1-NR] vs 7.2 [95% CI 5.6-9.2] mo; HR, 0.42 [95% CI 0.31-0.58]; P < 0.0001). PFS per IRC were consistent with INV assessment (Table). The benefit of dalpiciclib extended beyond initial study treatment based on time to first subsequent chemotherapy (TFSCT; HR, 0.47 [95% CI 0.32-0.69]; P < 0.0001). OS data were not mature with a total of 25 deaths documented. Median duration of exposure was 9.4 (IQR, 4.3-11.4) mo with dalpiciclib and 9.9 (4.7-11.9) mo with fulvestrant in the dalp-fulv group and was 6.1 (3.7-11.0) mo with fulvestrant in the PBO-fulv group. The most common (incidence ≥3%) grade 3 or 4 AEs with dalp-fulv were neutropenia (84.2%; vs 0% with PBO-fulv) and leukopenia (62.1%; vs 0%). Treatment discontinuation due to AE was reported for 2.5% of pts with dalp-fulv vs 3.3% with PBO-fulv. The incidence of SAE was 5.8% with dalp-fulv vs 6.7% with PBO-fulv. Conclusions: The study met its primary endpoint, demonstrating that dalpiciclib plus fulvestrant significantly improved PFS versus placebo plus fulvestrant, with a manageable safety profile. Our findings support dalpiciclib plus fulvestrant as a new treatment option in pts with HR+/HER2- ABC who relapsed or progressed on endocrine therapy. Clinical trial information: NCT03927456 .[Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优雅的士萧完成签到,获得积分10
刚刚
十一完成签到,获得积分10
刚刚
耳喃发布了新的文献求助10
刚刚
刚刚
赘婿的应助被元儿采纳,获得30
1秒前
1秒前
白耀庭完成签到,获得积分10
1秒前
耍酷平凡完成签到,获得积分10
1秒前
凪启完成签到,获得积分10
1秒前
酒石酸完成签到,获得积分10
1秒前
1秒前
liney发布了新的文献求助10
2秒前
梓齊发布了新的文献求助10
2秒前
2秒前
2秒前
YPHCC发布了新的文献求助10
2秒前
凶狠的乐巧完成签到,获得积分10
2秒前
2秒前
立冬完成签到,获得积分10
3秒前
开心的白米饭完成签到,获得积分10
3秒前
赘婿的应助被向大闹闹采纳,获得10
3秒前
风吹麦浪发布了新的文献求助10
4秒前
Huo完成签到 ,获得积分10
4秒前
小蘑菇的应助被晚秋采纳,获得30
4秒前
酆雅柔完成签到,获得积分10
4秒前
165完成签到,获得积分10
4秒前
4秒前
4秒前
物理光发布了新的文献求助10
5秒前
TQZZ发布了新的文献求助10
6秒前
大个的应助被henkey采纳,获得10
6秒前
大魁完成签到,获得积分10
6秒前
6秒前
yipmyonphu的应助被星空采纳,获得10
6秒前
7秒前
xxxwww完成签到,获得积分10
7秒前
朴实的火龙果完成签到,获得积分10
7秒前
风吹麦浪发布了新的文献求助10
7秒前
一二发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105